(Q33405154)

26 July 2017

Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience (English)

1 reference

26 July 2017

0 references

1 reference

1 reference

relapsed medulloblastoma

1 reference

1 reference

Dolly Aguilera

1

1 reference

26 July 2017

Claire Mazewski

2

1 reference

26 July 2017

Jason Fangusaro

3

1 reference

26 July 2017

Tobey J MacDonald

4

1 reference

26 July 2017

Rene Y McNall-Knapp

5

1 reference

26 July 2017

Laura L Hayes

6

1 reference

26 July 2017

Sungjin Kim

7

1 reference

26 July 2017

Robert C Castellino

8

1 reference

26 July 2017

8 January 2013

1 reference

26 July 2017

Child's Nervous System

1 reference

26 July 2017

29

1 reference

26 July 2017

4

1 reference

26 July 2017

589-596

1 reference

https://scigraph.springernature.com/pub.10.1007/s00381-012-2013-4

26 July 2017

0 references

cites work

Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Chronic oral VP-16 for recurrent medulloblastoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

The effect of M-stage on patterns of failure in posterior fossa primitive neuroectodermal tumors treated on CCG-921: a phase III study in a high-risk patient population

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Reirradiation of primary CNS tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Response of recurrent medulloblastoma to low-dose oral etoposide

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3963487

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

21 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Surveillance scanning of children with medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Array CGH analysis of pediatric medulloblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Reirradiation for recurrent medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Results of three-dimensional stereotactically-guided radiotherapy in recurrent medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Efficacy of temozolomide for recurrent embryonal brain tumors in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

High microvessel density in primitive neuroectodermal brain tumors of childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00381-012-2013-4

Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23296323

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00381-012-2013-4

1 reference

Dimensions Publication ID

26 July 2017

1015916183

0 references

Fatcat ID

release_xnesqbjumfhdrmyvbr5g3bcylm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xnesqbjumfhdrmyvbr5g3bcylm

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMCID

3963487

1 reference

26 July 2017

1 reference